



# Cisplatin

Lungenkarzinom, nicht-kleinzellig (NSCLC) » Stadium IB-III A

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Alexanderplatz 1  
10178 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Lorenz Trümper

Telefon: +49 (0)30 27 87 60 89 - 0  
Telefax: +49 (0)30 27 87 60 89 - 18

[info@dgho.de](mailto:info@dgho.de)  
[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

|  |          |
|--|----------|
| <b>1 Adjuvant chemotherapy, NSCLC, Stage IB - IIIA .....</b> | <b>2</b> |
|--|----------|

# Cisplatin

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » Stadium IB-IIIa

**Stand:** Juli 2021

## 1 Adjuvant chemotherapy, NSCLC, Stage IB - IIIA

### Adjuvant chemotherapy, NSCLC, Stage IB - IIIA

| onkopedia                    |                                   |                        |                | Facts   | Appraisal |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|------------------------------|-----------------------------------|------------------------|----------------|---|-----------|--|--|--|--|--|--|---|---|---|---|----|----|----|----|----|----|----|--|---|---|----|----|----|----|----|----|----|----------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|------------------------------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|---|---|---|---|---|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| <b>Parameter</b>             | <b>Results<sup>14</sup></b>       | <b>HR<sup>15</sup></b> | <b>p value</b> | <table style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="10"></td> <td style="text-align: center;">5</td> <td style="text-align: center;">4</td> <td style="text-align: center;">3b</td> <td style="text-align: center;">3a</td> <td style="text-align: center;">2c</td> <td style="text-align: center;">2b</td> <td style="text-align: center;">2a</td> <td style="text-align: center;">1b</td> <td style="text-align: center;">1a</td> </tr> <tr> <td colspan="10">Evidence (LoE)</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="background-color: black; width: 20px; height: 20px;"></td> </tr> <tr> <td colspan="10">Clinical benefit (ESMO MCBS)</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> <tr> <td colspan="10"></td> <td style="text-align: center;">1</td> <td style="text-align: center;">2</td> <td style="text-align: center;">3</td> <td style="text-align: center;">4</td> <td style="text-align: center;">5</td> <td colspan="5"></td> </tr> <tr> <td colspan="10"></td> <td style="text-align: center;"><span style="color: blue;">■</span> curative</td> <td colspan="9" style="text-align: center;"><span style="color: yellow;">■</span> non-curative</td> </tr> </table> |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  | 5 | 4 | 3b | 3a | 2c | 2b | 2a | 1b | 1a | Evidence (LoE) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Clinical benefit (ESMO MCBS) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 2 | 3 | 4 | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | <span style="color: blue;">■</span> curative | <span style="color: yellow;">■</span> non-curative |  |  |  |  |  |  |  |  |
|                              |                                   |                        |                |   |           |  |  |  |  |  |  |   |   | 5 | 4 | 3b | 3a | 2c | 2b | 2a | 1b | 1a |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Evidence (LoE)               |                                   |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Clinical benefit (ESMO MCBS) |                                   |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                              |                                   |                        |                |   |           |  |  |  |  | 1  | 2  | 3 | 4 | 5 |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                              |                                   |                        |                |   |           |  |  |  |  | <span style="color: blue;">■</span> curative | <span style="color: yellow;">■</span> non-curative |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>DFS<sup>4</sup></b>       | 20.7                              | vs 36.3                | p = 0.002      |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>OS<sup>5</sup></b>        | 43.7                              | vs 65.7                | p = 0.017      |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>Patients</b>              | Stage IB-IIIa, after R0 resection |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>Trial</b>                 | ANITA, phase 3                    |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>Randomisation</b>         | 1 : 1                             |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>N<sup>1</sup></b>         | 840                               |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>New Therapy</b>           | Platin+Vinorelbine                |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>Control</b>               | Observation                       |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| <b>Publication</b>           | DOI:10.1016/S1470-2045(06)70804-X |                        |                |   |           |  |  |  |  |  |  |   |   |   |   |    |    |    |    |    |    |    |  |   |   |    |    |    |    |    |    |    |                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |                              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Legende:

<sup>1</sup> N - number of patients

<sup>4</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy